# SANA — slm-full-cpu

## Metadata

ticker: SANA
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 53c792d2a4c958ca99c8662415c65ce3ff52d3bf793b3948323415937bbc252c
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 524, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 169.116, "latency_s_total": 169.116, "parse_failure": 0, "prompt_tokens": 2059, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 336, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 144.771, "latency_s_total": 144.771, "parse_failure": 0, "prompt_tokens": 2048, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 142, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 40.35, "latency_s_total": 40.35, "parse_failure": 0, "prompt_tokens": 621, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 171, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 56.721, "latency_s_total": 56.721, "parse_failure": 0, "prompt_tokens": 615, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 142, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 49.907, "latency_s_total": 49.907, "parse_failure": 0, "prompt_tokens": 410, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 148, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 66.71, "latency_s_total": 66.71, "parse_failure": 0, "prompt_tokens": 606, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 927, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 145.174, "latency_s_total": 145.174, "parse_failure": 0, "prompt_tokens": 1588, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 2.76,
  "currency": "USD",
  "market_cap": 826235392.0,
  "forward_pe": -4.9719877,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "financial_currency": "USD",
  "net_income": -211822000.0,
  "profit_margin_pct": 0.0,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-03",
    "summary": "Item 1A. Ris k Factors. Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report, including our financial statements and related notes included elsewhere in this Annual Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect o"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-10",
    "summary": "Item 1A. Ri sk Factors Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Quarterly Report, including our financial statements and related notes included elsewhere in this Quarterly Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely aff"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filings for ticker SANA, the key takeaways regarding risk factors and business outlook include:

**1. Unproven Technology and Development Risks**
*   The company’s *ex vivo* and *in vivo* cell engineering platforms rely on novel technologies that are unproven and may not result in approvable or marketable products.
*   There are no FDA-approved therapeutics currently known that are cell products derived from pluripotent stem cells (PSCs) or utilize the company’s fusogen technology.
*   Scientific evidence supporting these platforms is preliminary, limited, and ongoing. Preclinical and clinical testing is inherently unpredictable, and results from animal models or preclinical cell lines may not accurately predict safety and efficacy in humans.
*   The company has not tested its platforms on all cell types or microenvironments, and results may not translate across different contexts.

**2. Regulatory and Safety Challenges**
*   The company faces difficulties in creating appropriate models and assays to evaluate the safety and purity of its product candidates.
*   There is a risk that regulatory authorities may not be satisfied with the data provided to explain unexpected results observed during testing.
*   Novel gene editing reagents and manufacturing materials may have unanticipated or undesirable effects on safety, efficacy, or manufacturability, potentially affecting multiple programs and causing delays.

**3. Financial and Operational Uncertainties**
*   There is substantial doubt as to the company’s ability to continue as a going concern.
*   The company requires additional funding to finance operations. Failure to raise capital when needed could force the delay, reduction, or elimination of product development programs or commercialization efforts.
*   If the company fails to successfully identify, develop, and commercialize product candidates, or experiences significant delays, its business, financial condition, and results of operations will be materially adversely affected.

**4. Strategic and Personnel Risks**
*   The company may not realize the benefits of acquired or in-licensed technologies, nor may it successfully enter into new strategic relationships.
*   Future growth depends on retaining key personnel and recruiting additional qualified staff.
*   Managing growth, particularly in development and regulatory capabilities, may lead to operational disruptions.

**5. Forward-Looking Statements**
*   Forward-looking statements are based on current expectations and estimates but are subject to significant uncertainties. Actual results may differ materially from those expressed or implied.
*   The company does not undertake an obligation to publicly update any forward-looking statements.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Unproven Technology and Product Development:** The company’s ex vivo and in vivo cell engineering platforms are based on novel technologies that are unproven and may not result in approvable or marketable products. There is substantial doubt regarding the feasibility of developing therapeutic treatments based on these platforms, as scientific evidence is preliminary and limited.
*   **Regulatory and Clinical Uncertainty:** Preclinical and clinical testing is inherently unpredictable. Most current data are limited to animal models and preclinical assays, which may not accurately predict safety and efficacy in humans. There is a risk that the company may not be able to provide sufficient data to regulatory authorities to satisfy safety and purity requirements.
*   **Financial and Operational Risks:** There is substantial doubt as to the company’s ability to continue as a going concern. The company requires additional funding to finance operations; failure to raise capital when needed could force delays, reductions, or eliminations of product development programs.
*   **Strategic and Partnership Risks:** The company may not realize the benefits of acquired or in-licensed technologies, nor may it successfully enter into or realize benefits from new strategic relationships.
*   **Personnel and Growth Management:** The company’s ability to develop platforms and achieve future growth depends on retaining key personnel and recruiting qualified staff. Additionally, the company may encounter difficulties in managing growth, which could disrupt operations.
*   **General Business Risks:** If the company is unable to successfully identify, develop, and commercialize product candidates, or experiences significant delays, its business, financial condition, and results of operations will be materially adversely affected.

## Pre-written sections (judge input)

### Financial Health

Sana Biotechnology, Inc. (SANA) is currently trading at $2.76, reflecting a market capitalization of approximately $826.2 million. The company reports a negative forward P/E ratio of -4.97 and a net income of -$211.8 million, indicating it is not yet profitable. While specific revenue figures are not provided in the current dataset, the 0.0% profit margin underscores the firm's reliance on capital raises to fund its biotechnology operations. Investors should note that the stock is trading near its 52-week low of $2.61, highlighting significant near-term volatility and financial risk.

### Recent Developments

Sana Biotechnology, Inc. (SANA) continues to navigate significant financial headwinds, evidenced by a trailing net loss of $211.8 million and a negative forward P/E ratio, underscoring the company's ongoing reliance on capital markets for liquidity. The stock has traded near its 52-week low of $2.61, currently hovering at $2.76, reflecting investor caution amid persistent profitability challenges and a zero dividend yield. Recent SEC filings, including the 10-K and 10-Q reports, reiterate substantial risk factors related to geopolitical and economic uncertainties that could materially adversely affect operations. For investors, these developments highlight the high-risk nature of the position, necessitating careful consideration of the company's cash burn rate and execution capabilities in its gene therapy pipeline.

### SEC Filing Highlights
Sana Biotechnology faces substantial doubt regarding its ability to continue as a going concern, necessitating additional capital to fund ongoing operations and avoid potential delays or elimination of development programs. The company’s novel *ex vivo* and *in vivo* cell engineering platforms remain unproven, with no FDA-approved therapeutics currently existing in these specific categories, leading to inherent scientific and regulatory uncertainties. Significant risks include the unpredictability of preclinical and clinical results, potential safety issues from novel gene editing reagents, and challenges in establishing appropriate assays for product purity. Furthermore, the business outlook is heavily dependent on retaining key personnel and successfully executing strategic relationships, as failure to commercialize candidates could materially adversely affect financial conditions.

### Risk Factors

*   **Unproven Technology and Product Development:** The company’s novel ex vivo and in vivo cell engineering platforms are based on preliminary scientific evidence with substantial doubt regarding their feasibility to yield approvable or marketable therapeutic treatments.
*   **Regulatory and Clinical Uncertainty:** Current data is largely limited to animal models and preclinical assays, creating significant risk that the company cannot demonstrate sufficient safety and efficacy to satisfy regulatory authorities for human trials.
*   **Financial Viability and Capital Needs:** There is substantial doubt regarding the company’s ability to continue as a going concern, as failure to secure additional funding could force the delay, reduction, or elimination of critical product development programs.

## Audited (Exec Summary + Outlook)

### Executive Summary
Sana Biotechnology is a cell engineering company developing novel *ex vivo* and *in vivo* platforms, currently trading at $2.76 with a market capitalization of approximately $826.2 million despite reporting a net loss of -$211.8 million. The stock is notable for its proximity to the 52-week low of $2.61 and the substantial doubt regarding its ability to continue as a going concern, highlighting extreme financial fragility. The single most important near-term variable is the company's ability to secure additional capital to fund ongoing operations without delaying or eliminating critical development programs.

### Outlook
The directional outlook for Sana Biotechnology is cautiously cautious, characterized by severe execution risk and existential financial pressure. While the underlying cell engineering technology offers potential long-term differentiation, the immediate headwinds of unproven platforms and substantial doubt regarding the company's ability to continue as a going concern dominate the investment thesis. Investors should closely monitor the company's cash burn rate and its success in securing necessary liquidity, as failure to raise capital would likely result in the delay or elimination of development programs. The view would only strengthen if the company demonstrates clear progress in validating its *ex vivo* and *in vivo* platforms through positive preclinical or clinical data while simultaneously securing robust financial backing; conversely, any further dilution or inability to retain key personnel would significantly weaken the thesis.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "currently trading at $2.76"
LABEL: SUPPORTED
REASON: The raw source data explicitly lists `"current_price": 2.76`.

---

CLAIM: "market capitalization of approximately $826.2 million"
LABEL: SUPPORTED
REASON: The raw source data lists `"market_cap": 826235392.0`, which rounds to approximately $826.2 million.

---

CLAIM: "net loss of -$211.8 million"
LABEL: SUPPORTED
REASON: The raw source data lists `"net_income": -211822000.0`, which rounds to -$211.8 million.

---

CLAIM: "proximity to the 52-week low of $2.61"
LABEL: SUPPORTED
REASON: The raw source data explicitly lists `"week_52_low": 2.61`, and the current price of $2.76 is arithmetically close to that figure (difference of $0.15).

---

**OUTLOOK**

---

CLAIM: "failure to raise capital would likely result in the delay or elimination of development programs"
LABEL: SUPPORTED
REASON: The SEC Filing Highlights and RAG sections explicitly state that "failure to raise capital when needed could force the delay, reduction, or elimination of product development programs."

---

*No additional quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers appear in the Outlook section beyond the qualitative/directional statements already addressed. All named quantitative claims in both sections have been evaluated above.*
